Back to search

Cornell University

DEVELOPMENT OF HDAC11 INHIBITORS AND THEIR APPLICATION IN KRAS-DRIVEN CANCERS

Abstract

dc:description.abstract

HDAC11 is the most recently discovered and the least studied HDAC. In recent years, it has been reported to have crucial roles in immune function, metabolism, and tumorigenesis. During my Ph.D., I have worked on developing selective HDAC11 inhibitors that do not impede other HDAC’s activity and exploring natural products as a potential HDAC11 inhibitor such as Garcinol. I then applied my developed inhibitors in different types of cancer cells. Surprisingly, HDAC11 inhibition potently suppressed the anchorage-independent growth of KRAS dependent pancreas and colon cancer cells. Our preliminary data suggest that HDAC11 inhibitors could be potential therapeutics for KRAS-driven cancers and may provide a possible solution for the long-term challenge of targeting KRAS.

Degree

thesis:*
Name thesis:degree_name
Ph. D., Chemistry and Chemical Biology
Level thesis:degree_level
Doctor of Philosophy
Discipline thesis:degree_discipline
Chemistry and Chemical Biology
Grantor
Cornell University
Year dc:date.issued
2020

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Son, Se In
Chair dc:contributor.chair
  • Lin, Hening
Committee members dc:contributor.committeemember
  • Schroeder, Frank
  • Chang, Pamela V.

Subjects

dc:subject × 4

Rights

Language dc:language.iso
en

Identifiers

dc:identifier.*
Dc Identifier Bibid
13277725
Dc Identifier Other
ProQuest Submission ID: 12071
ProQuest Publication ID: 28003001

Chain of custody

source
Harvested from
Cornell University
Base URL
ecommons.cornell.edu/server/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Son, Se In. DEVELOPMENT OF HDAC11 INHIBITORS AND THEIR APPLICATION IN KRAS-DRIVEN CANCERS. Doctor of Philosophy thesis, Cornell University, 2020. https://hdl.handle.net/1813/103028